The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, In Hwa Um et al.|Clinical Cancer Research|2021Cited by 44
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patientsSarah P. Blagden, David J. Harrison, S.N. Symeonides et al.|Annals of Oncology|2024Cited by 3
Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738Hagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Cancer Research|2021Cited by 1
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Aglaia Skolariki et al.|Molecular Cancer Therapeutics|2023Cited by 1
Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapyAlison L. Dickson, David J. Harrison, In Hwa Um et al.|Cancer Research|2024Cited by 1